5-HT receptors (Serotonin receptors) are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems.5-HT1, 5-HT2, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 are the types. Both excitatory and inhibitory neurotransmission is mediated by them. The neurotransmitter serotonin, which serves as their inherently ligand, stimulates the serotonin receptors. Numerous neurotransmitters and hormones are released in response to stimulation of the serotonin receptors. Numerous biological and neurological functions, including aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation, are influenced by serotonin receptors. Many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens are among the pharmaceuticals that target the serotonin receptors.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V71121 | NAS-181 dimesylate | 1217474-40-2 | NAS181 is a potent and specific rat 5-HT1B receptor antagonist (inhibitor) with a Ki of 47 nM. |
|
V26538 | NLX-101 (F-15599) | 635323-95-4 | NLX-101, formerly known as F-15599, is a G-protein biased compound that activates serotonin 5-HT1A receptors with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors. |
|
V3103 | Ocaperidone (R79598) | 129029-23-8 | Ocaperidone (R-79598; R79598) is a potent and effective benzisoxazolyl piperidine neuroleptic and antipsychotic acting as an antagonist of 5-HT2, dopamine D2 and a 5-HT1A, with Ki values of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT2, a1-adrenergic receptor, dopamine D2, histamine H1 and a2-adrenergic receptor, respectively. |
|
V0963 | Olanzapine (LY170053) | 132539-06-1 | Olanzapine (formerly LY-170052, LY 170052, Zyprexa, Zolafren),a thienobenzodiazepine analog, is an approved atypical antipsychotic drug with high affinity for 5-HT2 serotonin and D2 dopamine receptor. |
|
V0975 | Ondansetron (GR 38032; SN 307; GR-C507/75) | 99614-02-5 | Ondansetron (GRC-50775; GR-38032; SN-307; GR38032; SN307; GR-C507/75; Zofran), an approved antiemetic drug, is a potent serotonin 5-HT3 receptor antagonist which is used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy. |
|
V0997 | Ondansetron HCl (GR 38032; SN 307; GR-C507/75) | 99614-01-4 | Ondansetron HCl (formerly GR 38032F, GR-C507/75; SN307; GR-C507/75; GRC-50775; GR-38032; SN-307; GR38032; Zofran) is an anti-emetic drug that acts as a potent serotonin 5-HT3 receptor antagonist. |
|
V71163 | Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) | 103639-04-9 | Ondansetron (GR 38032) HCl dehydrate is an orally bioavailable, selective and competitive 5-HT3 receptor antagonist (BBB (blood-brain barrier) permeable (penetrable)). |
|
V71227 | Ondansetron-d3 (GR 38032-d3; SN 307-d3) | 1132757-82-4 | Ondansetron-d3 is the deuterium labelled form of Ondansetron. |
|
V71212 | Ondansetron-d5 (GR 38032-d5; SN 307-d5) | 1219798-86-3 | Ondansetron-d5 is the deuterium labelled form of Ondansetron. |
|
V71210 | Ondansetron-d6 hydrochloride (GR 38032-d6 hydrochloride; SN 307-d6 hydrochloride) | 1225442-22-7 | Ondansetron-d6 ( HCl) is the deuterium labelled form of Ondansetron HCl. |
|
V71155 | Org-12962 hydrochloride | 210821-63-9 | Org 12962 HCl is a potent and specific 5-HT2C receptor agonist/activator with pEC50s of 7.01, 6.38 and 6.28 for 5-HT2C, 5-HT2A and 5-HT2B respectively. |
|
V3895 | Palonosetron | 135729-61-2 | Palonosetron (formerly RS-25259, RS-25259 197; trade name:Aloxi andAkynzeo) is a 5-HT3 antagonist approved for use in the prevention and treatment of chemotherapy-induced nausea and vomiting. |
|
V1022 | Palonosetron HCl (RS25233-197; Aloxi) | 135729-62-3 | Palonosetron HCl (formerly RS-25259, RS-25259,RS 25259 197, RS-25259197; trade names:Aloxi andAkynzeo), an approved antiemetic drug, is a potent 5-HT3 antagonist that has been used in the prevention and treatment of chemotherapy-induced nausea and vomiting. |
|
V71195 | Palonosetron-d3 hydrochloride (palonosetron d3 hydrochloride (HCl)) | 1246816-81-8 | Palonosetron-d3 ( HCl) is the deuterium labelled form of Palonosetron HCl. |
|
V3783 | Pardoprunox | 269718-84-5 | Pardoprunox (formerly known as SLV-308, DU-126891 or SME-308) is novel & potent dopamine D2/5-HT1A receptor agonist that has the potential for the treatment of Parkinson's disease. |
|
V3008 | Pardoprunox HCI | 269718-83-4 | Pardoprunox (formerly known as SLV-308, DU-126891 or SME-308) is novel & potent dopamine D2/5-HT1A receptor agonist that has the potential for the treatment of Parkinsons disease. |
|
V27338 | PF-04995274 | 1331782-27-4 | PF-04995274 (PF04995274) is a novel and potent serotonin 4 receptor (5-HT4) partial agonist,acting centrally as a pro-cognitive agent with the potential to be used for the treatment of Alzheimers disease (AD). |
|
V4625 | Piboserod | 152811-62-6 | Piboserod (SB 207266; trade name Serlipet) is a novel, potent and selective 5-HT(4) receptor antagonist marketed by GSK. |
|
V3349 | Pimavanserin | 706779-91-1 | Pimavanserin (formerly ACP-103; BVF-036; trade name Nuplazid) is an orally bioactive and selective inverse agonist of the 5-HT2A (serotonin receptor subtype 2A, pIC50 and pKd of 8.73 and 9.3, respectively)receptor approved asan atypical antipsychotic for the treatment of Parkinsons disease psychosis. |
|
V3350 | Pimavanserin tartrate | 706782-28-7 | Pimavanserin tartrate (formerly known as BVF036; ACP-103; BVF-036; Nuplazid), the tartrate salt of Pimavanserin, is a novel and orally bioactive inverse agonist of the 5-HT2A (serotonin receptor subtype 2A) receptor the has been approved in 2016 as an atypical antipsychotic for the treatment of Parkinson's disease psychosis. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
